Janssen Inc. company information, Employees & Contact Information

Leading where medicine is going Johnson & Johnson

Clinical trials Johnson & Johnson

Policies and reports Johnson & Johnson

Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate PR Newswire

U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated Johnson & Johnson

Janssen Provides Portfolio Update PR Newswire

Our culture of inclusion Johnson & Johnson

Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen's COVID-19 Vaccine Candidate PR Newswire

Johnson & Johnson: Changing health for humanity | J&J Switzerland Johnson & Johnson

Our Credo Johnson & Johnson

Our company Johnson & Johnson

Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat Johnson & Johnson

Johnson & Johnson Announces European Commission Approval for Janssen’s Preventive Ebola Vaccine Johnson & Johnson

Environmental sustainability Johnson & Johnson

Johnson & Johnson Announces Kenvue as the Name for Planned New Consumer Health Company Johnson & Johnson

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine Johnson & Johnson

Office of the Chief Medical Officer Johnson & Johnson

Global health equity Johnson & Johnson

ESG resources Johnson & Johnson

Suppliers Johnson & Johnson

Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. PR Newswire

Janssen to Acquire Investigational Bermekimab from XBiotech PR Newswire

Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023 PR Newswire

Meet Dr. Paul Janssen: A Legend in Pharmacology Johnson & Johnson

Janssen Reports Positive Top-line Phase 3 Study Results of Investigational, Long-acting Injectable HIV Treatment Regimen Administered Every Two Months PR Newswire

Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection PR Newswire

Johnson & Johnson Announces Donation of up to 500,000 Regimens of Janssen's Investigational Ebola Vaccine to Support Outbreak Response in Democratic Republic of the Congo (DRC) PR Newswire

Code of Business Conduct Johnson & Johnson

Janssen to Discontinue Pimodivir Influenza Development Program PR Newswire

Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases PR Newswire

Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supplemental New Drug Application to U.S. FDA for Treatment of Schizophrenia in Adults PR Newswire

Janssen Submits Ponesimod New Drug Application to the U.S. FDA for Treatment of Adults with Relapsing Multiple Sclerosis PR Newswire

Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting PR Newswire

Janssen Issues Voluntary Nationwide Recall for one lot of ORTHO-NOVUM® 1/35 and two lots of ORTHO-NOVUM® 7/7/7 Due to Incorrect Veridate® Dispenser Instructions PR Newswire

Janssen (Johnson & Johnson’s pharmaceutical segment) drugdiscoverytrends.com

Janssen Enters Into Worldwide Collaboration With Theravance Biopharma For Oral, Pan-JAK Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease PR Newswire

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV PR Newswire

Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection PR Newswire

Janssen to Highlight Latest Advances in Retina Portfolio at the European Society of Retina Specialists (EURETINA) 2023 Annual Meeting PR Newswire

Janssen Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis PR Newswire

Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions PR Newswire

Janssen Acquires Rights to Novel Gene Therapy, Pioneering Treatment Solutions for Late-Stage Age-Related Macular Degeneration PR Newswire

Janssen Launches Refreshed iMaGineMyMG Campaign for People Living With Myasthenia Gravis PR Newswire

Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior PR Newswire

U.S. FDA Approves INVOKANA® (canagliflozin) to Treat Diabetic Kidney Disease (DKD) and Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes (T2D) and DKD PR Newswire

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire

Janssen to Highlight Innovation in Retinal Pipeline at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting PR Newswire

Janssen Announces U.S. FDA Approval of SPRAVATO™ (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief PR Newswire

Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease PR Newswire

Janssen Expands Research & Development Presence with Major Investment in South San Francisco Business Wire

Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ GlobeNewswire

J&J to Compete in CAR-T: Subsidiary Janssen Biotech Signs $350M Deal with Legend Biotech BioInformant

Employees Johnson & Johnson

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression PR Newswire

Janssen to Highlight Innovation in Retinal Pipeline MultiVu

Janssen Announces Late-Breaking Data from Two Gene Therapy Programs MultiVu

Products Johnson & Johnson

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases PR Newswire

FDA Approves Stelara® (Ustekinumab) For Treatment Of Adults With Moderately To Severely Active Crohn’s Disease MultiVu

Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) MultiVu